Hjem › Multipelt myelom › Florida › Miami
Kliniske studier for Multipelt myelom i Miami, FL
21 studier for Multipelt myelom søker deltakere på steder i og rundt Miami (innen ca. 30 miles). Åpne et studie for å se hvem som kan delta og hvordan du kontakter studieteamet.
Offisiell studietekst (engelsk)
Rekrutterer til et studie her? Få det fremtredende øverst på siden – $99 i 30 dager →
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
RekruttererFase 1/2
- University of Miami, Miami
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
RekruttererFase 2
- University of Miami Sylvester Comprehensive Cancer Center, Miami
- University of Miami/Sylvester Cancer Institute - Alex's Place, Miami
- University of Miami/Sylvester Cancer Institute - Griffin Cancer Research Building, Miami
- og 2 flere
ERd Combination Treatment in Newly Diagnosed Multiple Myeloma (ADVANCE 2.0)
RekruttererFase 2
- University of Miami, Miami
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
RekruttererFase 3
- University of Miami Hospital and Clinics, Sylvester Cancer Center, Miami
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
RekruttererFase 2
- Miami Cancer Institute at Baptist Health, Inc., Miami
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
RekruttererFase 3
- Sylvester Comprehensive Cancer Center, Miami
- University of Miami Hospital and Clinics - Griffin Cancer Research Building, Miami
- University of Miami Hospital and Clinics, Miami
- og 3 flere
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
RekruttererFase 3
- Sylvester Comprehensive Cancer Center, Miami
- University of Miami Hospital and Clinics, Miami
- Sylvester Comprehensive Cancer Center - Kendall, Miami
IMMUNOPLANT for Newly Diagnosed Multiple Myeloma
RekruttererFase 2
- University of Miami, Miami
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
RekruttererFase 1
- University of Miami Don Soffer Clinical Research Center, Miami
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
RekruttererFase 1/2
- Research Site, Miami
A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
RekruttererFase 1
- University of Miami, Miami
Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)
RekruttererFase 4
- Sylvester Comprehensive Cancer Center, Miami
- University of Miami Hospital and Clinics - Griffin Cancer Research Building, Miami
- University of Miami Hospital and Clinics, Miami
FAST-M: Prolonged Overnight Fasting and Mediterranean Dietary Intervention for Patients With Multiple Myeloma or Its Precursor Disease
Rekrutterer
- University of Miami, Miami
Two Biologically and Clinically Distinct Entities: Progressive Versus Stable Multiple Myeloma (MM) Precursor Conditions
RekruttererObservasjonsstudie
- University of Miami Hospitals, Miami
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
RekruttererFase 1/2
- University of Miami, Miami
- Miami Cancer Institute, Miami
Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple Myeloma
RekruttererFase 2
- University of Miami, Miami
Teclistamab in Combination With Daratumumab for High-Risk Smoldering Myeloma: A Clinical and Correlative Phase 2 Immuno-Oncology Study (the REVIVE Study)
RekruttererFase 2
- University of Miami, Miami
Selinexor, Venetoclax, and Dexamethasone (XVenD) in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma
RekruttererFase 2
- University of Miami, Sylvester Comprehensive Cancer Center, Miami
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
RekruttererObservasjonsstudieFrivillige helsepersonell ønskes velkommen
- Miami Cancer Institute, Miami
Linvoseltamab in Addition to Lenalidomide (L2) During Maintenance Therapy of NDMM to Deepen Responses or Redrive MRD Negativity After Relapse
RekruttererFase 2
- University of Miami, Miami
CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
RekruttererFase 1
- Sylvester Comprehensive Cancer Center, University of Miami Hospital and Clinics, Miami
Multipelt myelom-studier i andre byer
- New York City, NY60 studier
- Boston, MA42 studier
- Atlanta, GA41 studier
- Houston, TX38 studier
- Durham, NC37 studier
- Nashville, TN32 studier
- Denver, CO27 studier
- Rochester, MN24 studier
- St. Louis, MO24 studier
- Columbus, OH24 studier
- Baldwin Park, CA23 studier
- Chicago, IL22 studier
Andre studier i Miami
- Brystkreft42 studier
- Kreft (alle typer)36 studier
- Ikke-småcellet lungekreft31 studier
- Prostatakreft27 studier
- Fedme27 studier
- Akut myelogen leukemi24 studier
- Metastatisk kreft24 studier
- Eggstokkreft23 studier
- Overvekt23 studier
- Ulcerøs kolitt21 studier
- Alzheimers sykdom20 studier
- Lungekreft20 studier
Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.